Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Southampton spin-out scoops major healthcare prize for revolutionary liver disease treatments

14.11.2005


Southampton-based company iQur has scooped the 2005 Medical Futures Department of Health Award for Best National Healthcare Innovation for its Hepatitis C diagnostic service, that can revolutionise the cost-effectiveness of treatment for Hepatitis C. iQur, formerly named HepCgen Limited, spun out from the University of Southampton in 2003.



The Medical Futures Innovations Awards are often referred to as the ‘Oscars of Healthcare’. iQur was presented with the Award for its research into the detection, treatment and monitoring of Hepatitis C and other liver diseases at the awards ceremony in London.

Accepting the Award from supermodel Caprice, Professor William Rosenberg, iQur’s founding Chief Scientific Officer and Professor of Hepatology at the University of Southampton, said: ‘This award is testament to the importance and success of our diagnostic services. iQur is the first Southampton-based company to be recognised at this level and we achieved this as a result of our expert team and their tremendous dedication to develop better care for the increasing threat of Hepatitis C across the globe. iQur’s strategies enable therapies to be tailored to the individual patient – potentially reducing treatment time and side effects, saving the NHS millions of pounds in clinical and pharmaceutical expenses. Following this innovation will be our simple blood test to reduce the requirement of serial liver biopsy across Europe, then the introduction of better treatment for Hepatitis C’


Speaking on behalf of the University of Southampton, Dr Tony Raven, Director of its Centre for Enterprise and Innovation (CEI) said, ‘Winning this very prestigious and hotly contested award is a fitting tribute to the work of Professor Rosenberg and his scientific team at iQur Limited.’ Earlier this year two other University of Southampton spin-out companies, SPI Lasers and OHM, were finalists in the Royal Academy of Engineering’s prestigious MacRobert Award, which recognises the successful development of innovative ideas in engineering. ‘The recognition our spin-out companies are receiving from these awards reflects the real commercial significance of our research and technology,’ he added.

As well as recognition within the medical community, iQur has also attracted positive attention from the investment community, and has successfully raised further investment of £2.6 million in an oversubscribed funding round. The funding will be used to establish the company’s Diagnostic Services business, the iQur® Speciality Pharmaceutical distribution division and grow various therapeutic in-licensing agreements.

Commenting on the investment and Award, David Norwood, Board Director and CEO of IP2IPO, a major investor in iQur, said: ‘UK universities are originators of some of the best novel intellectual property in the world, and the University of Southampton and the progress of the iQur team to deliver innovation to the global problem of liver disease, specifically, Hepatitis C, is an inspiration to all our portfolio companies, and fully reflective of our mission. iQur’s progress is underlined by the success of this financing round.’

In addition, iQur has also extended its focus and pipeline beyond Hepatitis C into liver fibrosis and secured a licensing deal with The University of Southampton. Liver fibrosis is the result of fatty liver disease, obesity, hepatitis, alcoholic liver disease and others. Over the last 20 years, the University has achieved an international reputation for its study of the pathology of fibrosis, cirrhosis, then cancer of the liver.

Commenting on these significant announcements, Paul Colford, CEO, said: ‘I am delighted that iQur’s ground breaking research into the diagnosis, treatment and monitoring of major liver diseases has been recognised on such a wide range of fronts, by the Department of Health, the investment community and the University, and underlines our company’s goal to become THE liver disease company.’

Sarah Watts | alfa
Further information:
http://www.soton.ac.uk

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>